The association of varying treatment thresholds of mepolizumab on asthma exacerbations in adults

References

• Centers for Disease Control. Most Recent National Asthma Data | CDC [Internet]; 2021. Available at: https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm
   Google Scholar
• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention; 2021.
   Google Scholar
• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013.
   PubMed Web of Science ®Google Scholar
• Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372(9643):1107–1119. doi:10.1016/S0140-6736(08)61452-X.
   PubMed Web of Science ®Google Scholar
• National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007;5 Suppl:120.
   Google Scholar
• Fala L. Nucala (mepolizumab): First IL-5 antagonist monoclonal antibody FDA approved for maintenance treatment of patients with severe asthma. Am Health Drug Benefits. 2016;9:106.
   PubMedGoogle Scholar
• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa1403291.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. doi:10.1016/S2213-2600(17)30125-X.
   PubMed Web of Science ®Google Scholar
• Harrison T, Canonica GW, Chupp G, Lee J, Schleich F, Welte T, Valero A, Gemzoe K, Maxwell A, Joksaite S, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020;56(4):2000151. doi:10.1183/13993003.00151-2020.
   PubMed Web of Science ®Google Scholar
• Platt R, Brown JS, Robb M, McClellan M, Ball R, Nguyen MD, Sherman RE. The FDA sentinel initiative—An evolving national resource. N Engl J Med. 2018;379(22):2091–2093. doi:10.1056/NEJMp1809643.
   PubMed Web of Science ®Google Scholar
• FDA Sentinel Initiative. Data | Sentinel Initiative. [Internet]. Available from: https://www.sentinelinitiative.org/sentinel/data.
   Google Scholar
• Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749–759. doi:10.1016/j.jclinepi.2010.10.004.
   PubMed Web of Science ®Google Scholar
• Israel E, Canonica GW, Brusselle G, Yang S, Howarth PH, Martin AL, et al. Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review. J Asthma. 2022;59(11):2201–2217.
   PubMed Web of Science ®Google Scholar
• Llanos J-P, Ortega H, Bogart M, Packnett ER, Manjelievskaia J, Bell CF, Hahn B. Real-world effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs. J Asthma Allergy. 2020;13:77–87. doi:10.2147/JAA.S236609.
   PubMed Web of Science ®Google Scholar
• van Toor JJ, van der Mark SC, Kappen JH, In’t Veen JCCM, Braunstahl GJ. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety. J Asthma. 2021;58(5):651–658. doi:10.1080/02770903.2020.1723623.
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, d’Ancona G, Elstad M, Green L, Fernandes M, Thomson L, Roxas C, Dhariwal J, Nanzer AM, Kent BD, et al. Real-world effectiveness and the characteristics of a “super-responder” to mepolizumab in severe eosinophilic asthma. Chest. 2020;158(2):491–500. doi:10.1016/j.chest.2020.03.042.
   PubMed Web of Science ®Google Scholar
• Taillé C, Chanez P, Devouassoux G, Didier A, Pison C, Garcia G, Charriot J, Bouée S, Gruber A, Pribil C, et al. Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Eur Respir J. 2020;55(6):1902345. doi:10.1183/13993003.02345-2019.
   PubMed Web of Science ®Google Scholar
• Sposato B, Camiciottoli G, Bacci E, Scalese M, Carpagnano GE, Pelaia C, Santus P, Maniscalco M, Masieri S, Corsico A, et al. Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life. Pulm Pharmacol Ther. 2020;61:101899. doi:10.1016/j.pupt.2020.101899.
   PubMed Web of Science ®Google Scholar
• Yilmaz İ, Türk M, Bahçecıoğlu S, Tutar N, Gülmez İ. Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study. Turk J Med Sci. 2020;50(2):433–441. doi:10.3906/sag-1912-62.
   PubMed Web of Science ®Google Scholar
• Matucci A, Vivarelli E, Bormioli S, Francesca N, Chiccoli F, Valentina M, Francesca G, Oliviero R, Parronchi P, Vultaggio A, et al. Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience. J Asthma. 2023;60(1):158–166. doi:10.1080/02770903.2022.2036754.
   PubMed Web of Science ®Google Scholar
• Crimi C, Campisi R, Nolasco S, Cacopardo G, Intravaia R, Porto M, Impellizzeri P, Pelaia C, Crimi N. Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: a real-world retrospective pilot study. Respir Med. 2021;185:106491. doi:10.1016/j.rmed.2021.106491.
   PubMed Web of Science ®Google Scholar
• Maglio A, Vitale C, Pelaia C, D’Amato M, Ciampo L, Sferra E, Molino A, Pelaia G, Vatrella A. Severe asthma remissions induced by biologics targeting IL5/IL5r: results from a multicenter real-life study. IJMS. 2023;24(3):2455. doi:10.3390/ijms24032455.
   Google Scholar
• Crimi C, Campisi R, Cacopardo G, Intravaia R, Nolasco S, Porto M, Pelaia C, Crimi N. Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities. World Allergy Organ J. 2020;13(9):100462. doi:10.1016/j.waojou.2020.100462.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Crimi C, Pelaia G, Nolasco S, Campisi R, Heffler E, Valenti G, Crimi N. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype. Clin Exp Allergy. 2020;50(7):780–788. doi:10.1111/cea.13613.
   PubMed Web of Science ®Google Scholar
• Moore WC, Kornmann O, Humbert M, Poirier C, Bel EH, Kaneko N, Smith SG, Martin N, Gilson MJ, Price RG, et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur Respir J. 2022;59(1):2100396. doi:10.1183/13993003.00396-2021.
   PubMed Web of Science ®Google Scholar
• Hendeles L, Khan YR, Shuster JJ, Chesrown SE, Abu-Hasan M. Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy. Ann Allergy Asthma Immunol. 2015;114(1):58–62.e2. doi:10.1016/j.anai.2014.10.012.
   PubMed Web of Science ®Google Scholar
• Carpagnano GE, Pelaia C, D’Amato M, Crimi N, Scichilone N, Scioscia G, Resta O, Calabrese C, Pelaia G, Quarato CMI, et al. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy. Ther Adv Respir Dis. 2020;14:175346662092923. doi:10.1177/1753466620929231.
   Web of Science ®Google Scholar
• Chapman KR, Albers FC, Chipps B, Muñoz X, Devouassoux G, Bergna M, Galkin D, Azmi J, Mouneimne D, Price RG, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716–1726. doi:10.1111/all.13850.
   PubMed Web of Science ®Google Scholar
• Liu MC, Chipps B, Munoz X, Devouassoux G, Bergna M, Smith SG, Price RG, Galkin DV, Azmi J, Mouneimne D, et al. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. Respir Res. 2021;22(1). doi:10.1186/s12931-021-01733-9.
   Web of Science ®Google Scholar
• Numata T, Araya J, Miyagawa H, Okuda K, Fujita Y, Utsumi H, Takekoshi D, Hashimoto M, Minagawa S, Ishikawa T, et al. Effectiveness of switching biologics for severe asthma patients in Japan: a single-center retrospective study. J Asthma Allergy. 2021;14:609–618. doi:10.2147/JAA.S311975.
   PubMed Web of Science ®Google Scholar
• Numata T, Miyagawa H, Nishioka S, Okuda K, Utsumi H, Hashimoto M, Minagawa S, Ishikawa T, Hara H, Araya J, et al. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study. BMC Pulm Med. 2020;20(1):207. doi:10.1186/s12890-020-01248-x.
   PubMed Web of Science ®Google Scholar
• Lam RW, Inselman JW, Jeffery MM, Maddux JT, Rank MA. National decline in asthma exacerbations in United States during coronavirus disease 2019 pandemic. Ann Allergy Asthma Immunol. 2021;127(6):692–694. doi:10.1016/j.anai.2021.09.017.
   PubMed Web of Science ®Google Scholar